Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus**

https://doi.org/10.1016/S0022-3476(79)80454-0Get rights and content

References (9)

There are more references available in the full text version of this article.

Cited by (163)

  • Patent Ductus Arteriosus in the Preterm Infant

    2023, Avery's Diseases of the Newborn
  • Optimizing practice guidelines through incorporating patient and family values and preferences

    2021, Seminars in Fetal and Neonatal Medicine
    Citation Excerpt :

    One of the most notable examples is the controversy around the management of PDA in preterm infants. PDAs in extremely preterm infants have been associated with – but not proven to cause - numerous adverse outcomes, including prolongation of assisted ventilation and pulmonary hemorrhage, CLD, NEC, IVH and death [24–28]. The mainstay of PDA treatment, cyclo-oxygenase inhibitors such as indomethacin and ibuprofen, are also associated with adverse outcomes such NEC, gastrointestinal perforation and renal failure [16,29].

  • Differential determinants of patent ductus arteriosus closure for prematurity of varying birth body weight: A Retrospective Cohort Study

    2020, Pediatrics and Neonatology
    Citation Excerpt :

    Patent ductus arteriosus (PDA) has been one of the most challenging daily issues in the majority of pediatric neonatal intensive care units (PNICUs). It causes some of the highest morbidity and mortality rates among preterm neonates,1 and it is associated with complications such as germinal matrix-intraventricular hemorrhage,2 congestive heart failure,3 chronic lung disease/bronchopulmonary dysplasia,4 and necrotizing enterocolitis.5 Ductus arteriosus (DA) occurs when a normal fetal blood vessel that connects the descending aorta and the main pulmonary artery and usually closes soon after birth.

  • Patent Ductus Arteriosus—Time for a Definitive Trial

    2020, Clinics in Perinatology
    Citation Excerpt :

    A PDA associated with clinical or echocardiographic signs of pulmonary hyperperfusion and systemic hypoperfusion is referred to as a hemodynamically significant PDA (hs-PDA). A persistent hs-PDA has been associated with numerous adverse outcomes, including higher rates of death,5 bronchopulmonary dysplasia (BPD),6 necrotizing enterocolitis (NEC),7 renal failure,4 intraventricular hemorrhage (IVH),8 periventricular leukomalacia,9 and cerebral palsy.10 A definitive causal link between these associations has not, however, been demonstrated.11

View all citing articles on Scopus
**

Preparation of the data for this report was aided by the efforts of Ms. Paula Langone, R.N. and Ms. Kathleen Finn, R.N.

View full text